Diego has more than two decades of venture capital experience and has developed a solid experience in creating, growing and exiting ventures in therapeutics and medical devices. He served as chairman and non-executive director in Endoart (acquired by Allergan), Endosense (acquired by St Jude), Picodrill (acquired by Asahi), Neocutis (acquired by Merz), Amal (acquired by Boehringer Ingelheim), Sequana (IPO on Euronext) and board observer to Genkyotex (IPO on Euronext).
Before entering the VC industry, Diego served as manager in several medical device and pharmaceutical companies.
Diego holds an M.Sc. in Microbiology from the Biocenter of the University of Basel and a PhD in Molecular and Cellular Biology from the Swiss Institute for Experimental Cancer Research (ISREC) in Lausanne.
Protein tags for labeling and purification
Technology to drill holes and cut glass - exited
Develop JNK inhibitors as treatment - exited
Small molecule NOX inhibitors - exited
Catheter ablation treatments - exited
Implantable batterie-less medical devices - exited
Develop oncology vaccine platform KISIMA - exited
Creams for treatment of vulvar issues - exited
Cosmeceuticals products for skin repair - exited